Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 Weeks

Key Takeaway
Consider sliding cupping as an alternative to NBUVB for plaque psoriasis with similar efficacy.

This randomized controlled trial evaluated the efficacy of sliding cupping therapy compared to narrowband ultraviolet B (NBUVB) therapy in 60 patients with plaque psoriasis. Participants were randomized to receive either sliding cupping or NBUVB treatment three times per week for eight weeks. The primary endpoint was the percentage reduction in Psoriasis Area and Severity Index (PASI) score at week 8. Results showed a mean percentage reduction in PASI of 62.4% (95% CI, 54.9-69.8) in the sliding cupping group and 66.9% (95% CI, 59.6-74.2) in the NBUVB group, with no significant difference between the groups (P=.526). Secondary endpoints, including Physician's Global Assessment (PGA), body surface area, and quality of life measures, also showed no significant differences between the groups at weeks 0, 4, 8, and 12. The total response rates were 69.23% for sliding cupping and 79.17% for NBUVB, which was not statistically significant (P=.526). Safety profiles were similar between the two treatments, with no significant adverse events reported. These findings suggest that sliding cupping therapy may be a viable alternative to NBUVB for managing plaque psoriasis, offering similar efficacy and safety.

AI Accuracy Review: 9/10 · Auto-published
View Original Abstract ↓
BACKGROUND: The sliding cupping therapy represents a traditional Chinese medicine therapy and receives much appreciation for treating plaque psoriasis. This study was designed to test the hypothesis that sliding cupping therapy is non-inferior to narrowband ultraviolet B (NBUVB) therapy in improving disease severity in patients with plaque psoriasis. METHODS: This prospective study recruited 60 patients with plaque psoriasis who were randomized to receive either sliding cupping intervention or NBUVB treatment. The cup was moved 30 times for each skin lesion until the target skin area turned purple. The initial dose (mJ/cm2) of ultraviolet radiation b (UVB) was determined based on sun-reactive skin types I through VI, which ranged from 300 mJ/cm2 to 800 mJ/cm2. Both treatments were performed 3 times per week for 8 weeks. The primary endpoint was the percentage reduction in Psoriasis Area and Severity Index (PASI) score at week 8, with secondary endpoints, including Physician's Global Assessment (PGA), body surface area, visual analogue scale scores, and quality of life measures. RESULTS: The total response rates were 69.23% (18/26) and 79.17% (19/24) for patients receiving sliding cupping intervention and those receiving NBUVB treatment, respectively, which showed no significant difference (P = .526). The PASI scores, body surface area, and PGA were reduced in patients with plaque psoriasis at W0, W4 and W8 after either sliding cupping intervention or NBUVB treatment (P <.001), and these reductions were not significantly different between the patients receiving sliding cupping intervention and those receiving NBUVB treatment at W0, W4, W8, and W12. At W8, the mean percentage reduction in PASI was 62.4% (95% CI, 54.9-69.8) in the sliding cupping group and 66.9% (95% CI, 59.6-74.2) in the NBUVB group, with no significant difference between groups. The total response rates were 69.23% (18/26) and 79.17% (19/24), respectively (P = .526). Patients receiving sliding cupping intervention and those receiving NBUVB treatment did not show statistically significant differences in these outcomes at W0, W4, W8, and W12 (P >.05). CONCLUSION: The overall results suggest that sliding cupping therapy exhibits statistically similar efficacy and safety profiles as NBUVB treatment, especially at 8 weeks after treatment.
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…